| Joshua Logan Breeden, MD | |
|
1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 | |
| (734) 936-4000 | |
| Not Available |
| Full Name | Joshua Logan Breeden |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 1500 E Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053809483 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301509467 (Michigan) | Primary |
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.
Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show.
A recent study published in Pediatrics and led by researchers at Columbia University Mailman School of Public Health found that sugar-sweetened beverages (SSBs) are an increasingly large part of children and teens' diets.
The Wall Street Journal reports: "Industry representatives met at the White House Tuesday with officials to consider specifics of a cost-saving agreement the industry reached last month with health-care negotiators and to discuss other concerns that the pharmaceutical industry has with the larger health-care overhaul being considered by Congress.
Solos Endoscopy, Inc. is pleased to announce that the Company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect November 24, 2010. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after November 24, 2010.
› Verified 9 days ago
| Entity Name | Metropolitan Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811937519 PECOS PAC ID: 5597651836 Enrollment ID: O20040507000012 |
News Archive
Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.
Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show.
A recent study published in Pediatrics and led by researchers at Columbia University Mailman School of Public Health found that sugar-sweetened beverages (SSBs) are an increasingly large part of children and teens' diets.
The Wall Street Journal reports: "Industry representatives met at the White House Tuesday with officials to consider specifics of a cost-saving agreement the industry reached last month with health-care negotiators and to discuss other concerns that the pharmaceutical industry has with the larger health-care overhaul being considered by Congress.
Solos Endoscopy, Inc. is pleased to announce that the Company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect November 24, 2010. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after November 24, 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Logan Breeden, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Joshua Logan Breeden, MD 1500 E Medical Center Dr, Ann Arbor, MI 48109-5000 Ph: (734) 936-4000 |
News Archive
Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced encouraging results of a preclinical toxicity study of azide drug-loaded Emulsiphan nano emulsions conducted with the National Cancer Institute (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone's proprietary nanoparticle drug delivery system.
Type 1 diabetes (T1D) is the third most common pediatric chronic disease in the United States, and the risk of the disease has risen sharply in non-Hispanic Black (NHB) children in the last 20 years, data show.
A recent study published in Pediatrics and led by researchers at Columbia University Mailman School of Public Health found that sugar-sweetened beverages (SSBs) are an increasingly large part of children and teens' diets.
The Wall Street Journal reports: "Industry representatives met at the White House Tuesday with officials to consider specifics of a cost-saving agreement the industry reached last month with health-care negotiators and to discuss other concerns that the pharmaceutical industry has with the larger health-care overhaul being considered by Congress.
Solos Endoscopy, Inc. is pleased to announce that the Company has completed a capital restructuring initiative as part of a previously announced recapitalization plan in order to position itself for growth over the next twelve months. The restructuring involved a common stock consolidation that took effect November 24, 2010. As a result of this announcement, the stock symbol will be changed temporarily to SNDYD for a period of 20 business days after November 24, 2010.
› Verified 9 days ago
Chiemezie Chianotu Amadi, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Patrick Charles Albus, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Michael James Todd, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Perry G Pernicano, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Ellen G Hoeffner, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Dr. Christopher Robert Nall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Stephen Michael Ascherl, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2375 Newport Rd, Ann Arbor, MI 48103 Phone: 734-327-0649 Fax: 734-327-0649 |